Triumeq (Abacavir/Dolutegravir/Lamivudi) Patent Expiration, LOE Window & CMS Spending
Triumeq (Abacavir/Dolutegravir/Lamivudi) by GSK: FDA Orange Book core substance LOE 2030-06-08, 0 AB generics, $850.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | GSK |
| FDA Application & Pathway | N205551 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2030-06-08 |
| Last Listed Patent or Exclusivity Date | 2030-06-08 |
| Orange Book Patents (*PED Extensions) | 4 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $850.5M |
| 2024 Medicare Part D Spend | $565.9M |
| 2024 Medicaid Spend | $284.6M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 17.8% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.